TY - JOUR
T1 - The International Sexual Health and REproductive Health during COVID-19 (I-SHARE) Study
T2 - A Multicountry Analysis of Adults from 30 Countries Prior to and during the Initial Coronavirus Disease 2019 Wave
AU - International Sexual Health And REproductive Health during COVID-19 Research Consortium
AU - Erausquin, Jennifer Toller
AU - Tan, Rayner K.J.
AU - Uhlich, Maximiliane
AU - Francis, Joel M.
AU - Kumar, Navin
AU - Campbell, Linda
AU - Zhang, Wei Hong
AU - Hlatshwako, Takhona G.
AU - Kosana, Priya
AU - Shah, Sonam
AU - Brenner, Erica M.
AU - Remmerie, Lore
AU - Mussa, Aamirah
AU - Klapilova, Katerina
AU - Mark, Kristen
AU - Perotta, Gabriela
AU - Gabster, Amanda
AU - Wouters, Edwin
AU - Burns, Sharyn
AU - Hendriks, Jacqueline
AU - Hensel, Devon J.
AU - Shamu, Simukai
AU - Marie Strizzi, Jenna
AU - Esho, Tammary
AU - Morroni, Chelsea
AU - Eleuteri, Stefano
AU - Sahril, Norhafiza
AU - Yun Low, Wah
AU - Plasilova, Leona
AU - Lazdane, Gunta
AU - Marks, Michael
AU - Olumide, Adesola
AU - Abdelhamed, Amr
AU - López Gómez, Alejandra
AU - Michielsen, Kristien
AU - Moreau, Caroline
AU - Tucker, Joseph D.
AU - Adebayo, Adedamola
AU - Adebayo, Emmanuel
AU - Ani Ahmad, Noor
AU - Brunet, Nicolás
AU - Kagesten, Anna
AU - Kemigisha, Elizabeth
AU - Kpokiri, Eneyi
AU - Maatouk, Ismael
AU - Manguro, Griffins
AU - Nimbi, Filippo M.
AU - Nobre, Pedro
AU - O'Hara, Caitlin
AU - Oyetunde, Oloruntomiwa
N1 - Funding Information:
This work was supported by the National Institutes of Health (NIH; UG3HD096929 and NIAID K24AI143471). In Latvia, this research was supported by the National Research Programme to Lessen the Effects of COVID-19 (VPP-COVID-2020/1-0011).
Publisher Copyright:
© 2022 The Author(s).
PY - 2022/7/1
Y1 - 2022/7/1
N2 - Background: There is limited evidence to date about changes to sexual and reproductive health (SRH) during the initial wave of coronavirus disease 2019 (COVID-19). To address this gap, our team organized a multicountry, cross-sectional online survey as part of a global consortium. Methods: Consortium research teams conducted online surveys in 30 countries. Sampling methods included convenience, online panels, and population-representative. Primary outcomes included sexual behaviors, partner violence, and SRH service use, and we compared 3 months prior to and during policy measures to mitigate COVID-19. We conducted meta-analyses for primary outcomes and graded the certainty of the evidence. Results: Among 4546 respondents with casual partners, condom use stayed the same for 3374 (74.4%), and 640 (14.1%) reported a decline. Fewer respondents reported physical or sexual partner violence during COVID-19 measures (1063 of 15 144, 7.0%) compared to before COVID-19 measures (1469 of 15 887, 9.3%). COVID-19 measures impeded access to condoms (933 of 10, 8.7%), contraceptives (610 of 8175, 7.5%), and human immunodeficiency virus/sexually transmitted infection (HIV/STI) testing (750 of 1965, 30.7%). Pooled estimates from meta-analysis indicate that during COVID-19 measures, 32.3% (95% confidence interval [CI], 23.9%-42.1%) of people needing HIV/STI testing had hindered access, 4.4% (95% CI, 3.4%-5.4%) experienced partner violence, and 5.8% (95% CI, 5.4%-8.2%) decreased casual partner condom use (moderate certainty of evidence for each outcome). Meta-analysis findings were robust in sensitivity analyses that examined country income level, sample size, and sampling strategy. Conclusions: Open science methods are feasible to organize research studies as part of emergency responses. The initial COVID-19 wave impacted SRH behaviors and access to services across diverse global settings.
AB - Background: There is limited evidence to date about changes to sexual and reproductive health (SRH) during the initial wave of coronavirus disease 2019 (COVID-19). To address this gap, our team organized a multicountry, cross-sectional online survey as part of a global consortium. Methods: Consortium research teams conducted online surveys in 30 countries. Sampling methods included convenience, online panels, and population-representative. Primary outcomes included sexual behaviors, partner violence, and SRH service use, and we compared 3 months prior to and during policy measures to mitigate COVID-19. We conducted meta-analyses for primary outcomes and graded the certainty of the evidence. Results: Among 4546 respondents with casual partners, condom use stayed the same for 3374 (74.4%), and 640 (14.1%) reported a decline. Fewer respondents reported physical or sexual partner violence during COVID-19 measures (1063 of 15 144, 7.0%) compared to before COVID-19 measures (1469 of 15 887, 9.3%). COVID-19 measures impeded access to condoms (933 of 10, 8.7%), contraceptives (610 of 8175, 7.5%), and human immunodeficiency virus/sexually transmitted infection (HIV/STI) testing (750 of 1965, 30.7%). Pooled estimates from meta-analysis indicate that during COVID-19 measures, 32.3% (95% confidence interval [CI], 23.9%-42.1%) of people needing HIV/STI testing had hindered access, 4.4% (95% CI, 3.4%-5.4%) experienced partner violence, and 5.8% (95% CI, 5.4%-8.2%) decreased casual partner condom use (moderate certainty of evidence for each outcome). Meta-analysis findings were robust in sensitivity analyses that examined country income level, sample size, and sampling strategy. Conclusions: Open science methods are feasible to organize research studies as part of emergency responses. The initial COVID-19 wave impacted SRH behaviors and access to services across diverse global settings.
KW - HIV
KW - condom use
KW - sexual behavior
KW - sexual violence
KW - sexually transmitted infections
KW - HIV Infections
KW - Sexual Behavior
KW - Cross-Sectional Studies
KW - Reproductive Health
KW - Humans
KW - Sexual Health
KW - Sexually Transmitted Diseases/epidemiology
KW - COVID-19
KW - Adult
KW - Condoms
KW - Sexual Partners
UR - http://www.scopus.com/inward/record.url?scp=85129770205&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85129770205&partnerID=8YFLogxK
U2 - 10.1093/cid/ciac102
DO - 10.1093/cid/ciac102
M3 - Article
C2 - 35136960
AN - SCOPUS:85129770205
SN - 1058-4838
VL - 75
SP - E991-E999
JO - Clinical Infectious Diseases
JF - Clinical Infectious Diseases
IS - 1
ER -